TransMedics Group (NASDAQ:TMDX) Shares Gap Up to $50.45
TransMedics Group (NASDAQ:TMDX) Shares Gap Up to $50.45
TransMedics Group, Inc. (NASDAQ:TMDX – Get Rating)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $50.45, but opened at $51.61. TransMedics Group shares last traded at $49.81, with a volume of 1,249 shares changing hands.
纳斯达克股票代码:TMDX-GET Rating)周二盘前股价暴涨,此前收盘价为50.45美元,开盘报51.61美元。
Wall Street Analysts Forecast Growth
华尔街分析师预测经济增长
TMDX has been the subject of several research reports. Morgan Stanley raised their price objective on shares of TransMedics Group from $34.00 to $37.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 3rd. Oppenheimer raised their price target on shares of TransMedics Group from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Tuesday, August 2nd. Cowen increased their price objective on TransMedics Group from $45.00 to $50.00 in a research report on Tuesday, August 2nd. JPMorgan Chase & Co. raised TransMedics Group from a "neutral" rating to an "overweight" rating and boosted their price objective for the stock from $26.00 to $48.00 in a report on Tuesday, August 2nd. Finally, Cowen raised their target price on shares of TransMedics Group from $39.00 to $45.00 and gave the company an "outperform" rating in a research note on Tuesday, July 26th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $46.00.
TMDX已经成为几份研究报告的主题。在8月3日星期三的一份研究报告中,摩根士丹利将TransMedics Group的股票目标价从34美元上调至37美元,并给予该公司“同等权重”的评级。在8月2日周二的一份报告中,奥本海默将TransMedics Group的股票目标价从40.00美元上调至45.00美元,并给予该公司“跑赢大盘”的评级。考恩在8月2日星期二的一份研究报告中将TransMedics Group的目标价从45.00美元上调至50.00美元。在8月2日周二的一份报告中,摩根大通将TransMedics Group的评级从中性上调至增持,并将该股的目标价从26.00美元上调至48.00美元。最后,考恩将TransMedics Group的股票目标价从39.00美元上调至45.00美元,并在7月26日(星期二)的一份研究报告中给出了该公司“跑赢大盘”的评级。一名投资分析师对该股的评级为持有,六名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,该股目前的平均评级为“中等买入”,平均目标价为46.00美元。
TransMedics Group Stock Down 1.8 %
TransMedics集团股价下跌1.8%
The company has a quick ratio of 3.41, a current ratio of 4.18 and a debt-to-equity ratio of 0.70. The firm has a fifty day simple moving average of $44.98 and a 200-day simple moving average of $32.77.
该公司的速动比率为3.41,流动比率为4.18,债务权益比率为0.70。该公司的50日简单移动均线为44.98美元,200日简单移动均线为32.77美元。
Insider Activity at TransMedics Group
TransMedics集团的内幕活动
In other TransMedics Group news, CEO Waleed H. Hassanein sold 2,277 shares of the company's stock in a transaction on Wednesday, September 7th. The shares were sold at an average price of $55.00, for a total transaction of $125,235.00. Following the sale, the chief executive officer now directly owns 464,008 shares of the company's stock, valued at $25,520,440. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other TransMedics Group news, VP John F. Carey sold 1,500 shares of the firm's stock in a transaction on Monday, July 11th. The stock was sold at an average price of $32.98, for a total transaction of $49,470.00. Following the completion of the sale, the vice president now owns 379 shares of the company's stock, valued at approximately $12,499.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Waleed H. Hassanein sold 2,277 shares of the company's stock in a transaction on Wednesday, September 7th. The shares were sold at an average price of $55.00, for a total transaction of $125,235.00. Following the completion of the transaction, the chief executive officer now owns 464,008 shares in the company, valued at $25,520,440. The disclosure for this sale can be found here. Over the last three months, insiders sold 183,905 shares of company stock valued at $7,240,928. 8.70% of the stock is owned by corporate insiders.
在TransMedics Group的其他消息中,首席执行官瓦利德·H·哈萨尼因在9月7日星期三的一笔交易中出售了2277股公司股票。这些股票以55.00美元的平均价格出售,总成交金额为125235.00美元。出售后,首席执行官现在直接持有464,008股公司股票,价值25,520,440美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,可以通过这个超级链接访问。在TransMedics Group的其他新闻中,副总裁约翰·F·凯里在7月11日星期一的一次交易中出售了1500股该公司的股票。该股以32.98美元的平均价格出售,总成交金额为49,470.00美元。出售完成后,副总经理总裁现在持有该公司379股股票,价值约12,499.42美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在美国证券交易委员会网站上查阅。此外,首席执行官瓦利德·H·哈萨尼因在9月7日星期三的一次交易中出售了2,277股公司股票。这些股票以55.00美元的平均价格出售,总成交金额为125235.00美元。交易完成后,首席执行官现在拥有该公司464,008股,价值25,520,440美元。此次拍卖的披露信息可在此处找到。在过去三个月里,内部人士出售了183,905股公司股票,价值7,240,928美元。8.70%的股份由企业内部人士持有。
Institutional Inflows and Outflows
机构资金流入和流出
Institutional investors and hedge funds have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new stake in TransMedics Group during the second quarter worth approximately $31,000. Prospera Financial Services Inc bought a new stake in TransMedics Group in the 2nd quarter valued at $69,000. Amalgamated Bank acquired a new position in TransMedics Group in the 1st quarter valued at $114,000. Ensign Peak Advisors Inc bought a new position in TransMedics Group during the 4th quarter worth $97,000. Finally, Captrust Financial Advisors lifted its holdings in shares of TransMedics Group by 738.8% during the first quarter. Captrust Financial Advisors now owns 5,788 shares of the company's stock worth $156,000 after buying an additional 5,098 shares in the last quarter. Institutional investors and hedge funds own 81.46% of the company's stock.
机构投资者和对冲基金最近买卖了该股的股票。FNY Investment Advisers LLC在第二季度收购了TransMedics Group价值约3.1万美元的新股份。普罗斯佩拉金融服务公司在第二季度购买了TransMedics Group的新股份,价值6.9万美元。合并银行在第一季度收购了TransMedics Group的一个新头寸,价值11.4万美元。Ensign Peak Advisors Inc.在第四季度购买了TransMedics Group的一个新头寸,价值97,000美元。最后,CapTrust Financial Advisors在第一季度增持了TransMedics Group的股票738.8%。CapTrust Financial Advisors现在拥有5,788股该公司股票,价值15.6万美元,上个季度又购买了5,098股。机构投资者和对冲基金持有该公司81.46%的股票。
TransMedics Group Company Profile
TransMedics集团公司简介
(Get Rating)
(获取评级)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
TransMedics Group,Inc.是一家商业阶段的医疗技术公司,致力于为美国和国际上的终末期器官衰竭患者改造器官移植疗法。该公司提供器官护理系统(OCS),这是一种便携式器官灌流、优化和监测系统,利用其专有和定制的技术来复制人体外捐赠器官的近生理条件。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
- Has AMD stock stock fallen too far?
- Oracle's Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- 免费获取StockNews.com关于TransMedics Group(TMDX)的研究报告
- AMD股票是不是跌得太厉害了?
- 甲骨文的短期痛苦可能是你的长期收益
- Lucid看起来像是电动汽车的赢家
- 仍然爱着它:投资者继续光顾麦当劳
- 联邦快递刚刚提供了一个买入机会吗?
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
接受TransMedics Group Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收TransMedics Group和相关公司的最新新闻和分析师评级的每日摘要。